Oralpharmacotherapy for erectile dysfunction: Current perspectives

Urology

Volumn 54, Issue 3, 1999, Pages 392-400

  Burnett, Arthur L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; ARGININE; LEVODOPA; LIMAPROST; NALTREXONE; PHENTOLAMINE; SILDENAFIL; TRAZODONE; YOHIMBINE;

DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; HUMAN; MALE; MOLECULAR BIOLOGY; ORAL DRUG ADMINISTRATION; PENIS ERECTION; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; IMPOTENCE;

ADMINISTRATION, ORAL; HUMANS; IMPOTENCE; MALE; PENILE ERECTION;

EID: 0033192432     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00200-9     Document Type: Review

References (59)

1. Jarow JP, Nana-Sinkam P, Sabbagh M, et al: Outcome analysis of goal directed therapy for impotence. J Urol 155: 1609-1612, 1996.
2. Hanash KA: Comparative results of goal oriented therapy for erectile dysfunction. J Urol 157: 2135-2138, 1997.
3. Morales A, Heaton JPW, Johnston B, et al: Oral and topical treatment of erectile dysfunction: present and future. Urol Clin North Am 22: 879-886, 1995.
4. NIH Consensus Development Panel on Impotence: Impotence. JAMA 270: 83-89, 1993.
5. Benet AE, and Melman A: The epidemiology of erectile dysfunction. Urol Clin North Am 22: 699-709, 1995.
6. Shabsigh R: Is a drug effect part of your patient's complaint of impotence? Contemp Urol 5: 51-61, 1993.
7. Saenz de Tejada I: Mechanisms for the regulation of penile smooth muscle contractility, in Lue TF (Ed): World Book of Impotence. London, Smith-Gordon, 1992, pp 39-48.
8. Andersson K-E, and Wagner G: Physiology of penile erection. Physiol Rev 75: 191-236, 1995.
9. Argiolas A, and Melis MR: Neuromodulation of penile erection: an overview of the role of neurotransmitters and neuropeptides. Prog Neurobiol 47: 235-255, 1995.
10. Giuliano FA, Rampin O, Benoit G, et al: Neural control of penile erection. Urol Clin North Am 22: 747-766, 1995.
11. Christ GJ: The penis as a vascular organ: the importance of corporal smooth muscle tone in the control of erection. Urol Clin North Am 22: 727-745, 1995.
12. Lue TF, and Iriye CA: Medical management of erectile dysfunction, in Walsh PC, Retik AB, Stamey TA, et al (Eds): Campbell's Urology: Update 22. Philadelphia, WB Saunders, 1997, pp 1-9.
13. Stief CG, Noack T, and Andersson K-E: Signal transduction in cavernous smooth muscle. World J Urol 15: 27-31, 1997.
14. Christ GJ: The "syncytial tissue triad": a model for understanding how gap junctions participate in the local control of penile erection. World J Urol 15: 36-44, 1997.
15. Burnett AL: Neurophysiology of erectile function and dysfunction, in Hellstrom WJG (Ed): The Handbook of Sexual Dysfunction. San Francisco, The American Society of Andrology, 1999, pp 12-17.
16. Rall TW: Formation and degradation of cyclic nucleotides: an overview, in Nathanson JA, and Kebabian CN (Eds): Handbook of Experimental Pharmacology. New York, Springer-Verlag, 1982, pp 3-16.
17. Stief CG, Uckert S, Becker AJ, et al: The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J Urol 159: 1390-1393, 1998.
18. +-ATPase in the regulation of human corpus cavernosum smooth muscle contractility by nitric oxide. Br J Pharmacol 116: 2201-2206, 1995.
19. Seftel AD, Viola DA, Kasner SE, et al: Nitric oxide relaxes rabbit corpus cavernosum smooth muscle via a potassium-conductive pathway. Biochem Biophys Res Commun 219: 382-387, 1996.
20. Steers WD: Current perspectives in the neural control of penile erection, in Lue TF (Ed): World Book of Impotence. London, Smith-Gordon, 1992, pp 23-32.
21. Zorgniotti AW, and Lizza EF: Effect of large doses of the nitric oxide precursor, L-arginine, on erectile dysfunction. Int J Impot Res 6: 33-35, 1994.
22. FDA resources page. Food and Drug Administration web site. Available at http://www.fda.gov/cder/consumerinfo/ viagra/default.htm. Accessed December 1998.
23. Boolell M, Allen MJ, Ballard SA, et al: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8: 47-52, 1996.
24. Jeremy JY, Ballard SA, Naylor AM, et al: Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 79: 958-963, 1997.
25. Moreland RB, Goldstein I, and Traish A: Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 62: 309-318, 1998.
26. Ballard SA, Gingell CJ, Tang K, et al: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159: 2164-2171, 1998.
27. Chuang AT, Strauss JD, Murphy RA, et al: Sildenafil, a type-5 cGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J Urol 160: 257-261, 1998.
28. Taher A, Meyer M, Stief CG, et al: Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol 15: 32-35, 1997.
29. Boolell M, Gepi-Atee S, Gingell JC, et al: Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78: 257-261, 1996.
30. Goldstein I, Lue TF, Padma-Nathan H, et al: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338: 1397-1404, 1998.
31. Derry F, Glass C, Dinsmore W, et al: Sildenafil (Viagra™): an oral treatment for men with erectile dysfunction caused by traumatic spinal cord injury - a 28 day, double-blind, placebo-controlled, parallel-group, dose-response study. Neurology 48: A215, 1997.
32. Wagner G, Mayton M, and Smith MD: Analysis of the efficacy of sildenafil (Viagra™) in the treatment of male erectile dysfunction in elderly patients (abstract). J Urol 159: 239, 1998.
33. Rendell MS, Rajfer J, Wicker PA, et al: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA 281: 421-426, 1999.
34. Pfizer, Viagra (sildenafil citrate) Package Insert. Revised November 1998.
35. Zippe CD, Kedia AW, Kedia K, et al: Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 52: 963-966, 1998.
36. Steers WD: Meta-analysis of the efficacy of sildenafil (Viagra™) in the treatment of severe erectile dysfunction (abstract). J Urol 159: 238, 1998.
37. Morales A, Gingell C, Collins M, et al: Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 10: 69-73, 1998.
38. Lal S, Laryea E, Thavundayil JX, et al: Apomorphine-induced penile tumescence in impotent patients - preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry 11: 235-242, 1987.
39. Heaton JPW, Morales A, Adams MA, et al: Recovery of erectile function by the oral administration of apomorphine. Urology 45: 200-206, 1995.
40. Padma-Nathan H, Fromm-Freeck S, Ruff DD, et al: Efficacy and safety of apomorphine sl vs placebo for male erectile dysfunction (MED) (abstract). J Urol 159: 241, 1998.
41. Horita H, Sato Y, Adachi H, et al: Effects of levodopa on nocturnal penile tumescence: a preliminary study. J Androl 19: 619-624, 1998.
42. Gwinup G: Oral phentolamine in non-specific erectile insufficiency. Ann Intern Med 109: 162-168, 1988.
43. Zorgniotti AW: Experience with buccal phentolamine mesylate for impotence. Int J Impot Res 6: 37-41, 1994.
44. Becker AJ, Stief CG, Machtens S, et al: Oral phentolamine as treatment for erectile dysfunction. J Urol 159: 1214-1216, 1998.
45. Goldstein I: Efficacy and safety of oral phentolamine (Vasomax) for the treatment of minimal erectile dysfunction (abstract). J Urol 159: 240, 1998.
46. Clark JT: Suppression of copulatory behaviour in male rats following central administration of clonidine. Neuropharmacology 30: 373-382, 1991.
47. Morales A, Surridge DG, Marshall PG, et al: Non-hormonal pharmacological treatment of organic impotence. J Urol 128: 45-47, 1982.
48. Ernst E, and Pittler MH: Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 159: 433-436, 1998.
49. Telöken C, Rhoden EL, Sogari P, et al: Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 159: 122-124, 1998.
50. Montague DK, Barada JH, Belker AM, et al: Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol 156: 2007-2011, 1996.
51. Carson CC, and Mino RD: Priapism associated with trazodone therapy. J Urol 139: 369-370, 1988.
52. Saenz de Tejada I, Ware JC, Blanco R, et al: Pathophysiology of prolonged penile erection associated with trazodone use. J Urol 165: 60-63, 1991.
53. Abber JC, Lue TF, Luo JA, et al: Priapism induced by chlorpromazine and trazodone: mechanism of action. J Urol 137: 1039-1042, 1987.
54. Kurt U, Ozkardes J, Altug U, et al: The efficacy of anti-serotoninergic agents in the treatment of erectile dysfunction. J Urol 152: 407-409, 1994.
55. Lance R, Albo M, Costabile RA, et al: Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review. Urology 46: 117-120, 1995.
56. Meinhardt W, Schmitz PIM, Kropman RF, et al: Trazodone, a double blind trial for treatment of erectile dysfunction. Int J Impot Res 9: 163-165, 1997.
57. Costabile RA, and Spevak M: Trazodone is not effective therapy for erectile dysfunction: the results of a placebo controlled, double blind study (abstract). J Urol 159: 240, 1998.
58. 1 on erectile dysfunction. Br J Urol 80: 772-775, 1997.
59. van Ahlen H, Piechota HJ, Kias HJ, et al: Opiate antagonists in erectile dysfunction: a possible new treatment option? Eur Urol 28: 246-250, 1995.